ArticleDigestive diseases and sciences2008
Long-term proton pump inhibitor use in children: a retrospective review of safety.
Article in Digestive diseases and sciences, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Balancing therapeutic benefits and hidden risks of proton pump inhibitors in pediatric practice: a narrative review and update.Clinical and experimental pediatrics · 2026Article
- Safety of Proton Pump Inhibitors in Pediatric Population: A Systematic Review.Global pediatric health · 2024Review
- Appropriateness of proton pump inhibitors use in noncritically ill hospitalized children in a tertiary hospital in Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Duration of Pediatric Clinical Trials Submitted to the US Food and Drug Administration.JAMA pediatrics · 2019Review
- Optimizing the Use of Medications and Other Therapies in Infant Gastroesophageal Reflux.Paediatric drugs · 2018Review
- Non-Specific Gastric Inflammation in Children is Associated with Proton Pump Inhibitor Treatment for More than 6 Weeks.Frontiers in pediatrics · 2014Article
- Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics.Paediatric drugs · 2013Review
- Failure of proton pump inhibitors to treat GERD in neonates and infants: a question of drug, diagnosis, or design.Clinical pharmacology and therapeutics · 2012Review
- Clinical utility of esomeprazole for treatment of gastroesophageal reflux disease in pediatric and adolescent patients.Adolescent health, medicine and therapeutics · 2012Review
- Cobalamin status in children.Journal of inherited metabolic disease · 2011Review
- Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium.Current gastroenterology reports · 2010Review
- Safety profile of six months lansoprozole treatment in children.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2010Article
- Delayed-release oral suspension of omeprazole for the treatment of erosive esophagitis and gastroesophageal reflux disease in pediatric patients: a review.Clinical and experimental gastroenterology · 2010Article
- Proton pump inhibitors: an update of their clinical use and pharmacokinetics.European journal of clinical pharmacology · 2008Review
- Long-term use of PPIs in children: we have questions.Digestive diseases and sciences · 2008Article
- New-onset constipation at acute stage after stroke: incidence, risk factors, and impact on stroke rehabilitation.Frontiers in neurologyArticle
- Rising Prevalence of Mild Chronic Gastritis in Children: A Single Center Experience.Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology SocietyArticle
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this work was to assess the efficacy of continuous proton pump inhibitor (PPI) therapy in children and to evaluate changes in biochemical, endoscopic, and histologic parameters during such treatment. A retrospective review of children receiving PPI therapy continuously for 1 year or more with baseline and follow-up esophageal and gastric biopsies on treatment was conducted to assess type, frequency, and duration of PPI dosing, symptom relief, gastrin levels, histologic findings, and adverse events. A total of 113 children (59 male, median age 4.5 years) were identified. Of these, 31% (35/113) were neurologically impaired. The median treatment duration was 35.2 months. Elevated serum gastrin levels occurred in 73% of children with no statistically significant differences in gastrin level by PPI type, dose, and dosing frequency or treatment duration. Adverse events were reported by 12% of children: diarrhea (5%) and constipation (4%) were the most frequent. Long-term PPI therapy appears to be effective, safe and well tolerated in children despite some biochemical, endoscopic, and histologic changes.
Indexed as
Identifiers
17676398What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.